Compare Neurocrine Biosciences Inc (NBIX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Valero Energy Corporation — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Valero Energy Corporation trades at $391.21 (market cap $110.23B). The key difference: Valero Energy Corporation is far larger — about 7× Neurocrine Biosciences Inc's market cap, and Valero Energy Corporation pays a 1.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VLO | |
|---|---|---|
Market Cap | $15.77B | $110.23B |
Sector | Health | Energy |
52-Week High | $185.50 | $388.95 |
52-Week Low | $123.10 | $156.39 |
Enterprise Value | $15.78B | $113.71B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Valero Energy (VLO) trades at $382.85, up 3.27% today, reflecting strong momentum amid favorable refining conditions. The stock exhibits a bullish technical trend, with recent earnings beats and a Zacks Rank #1 (Strong Buy) as of September 9, 2026. Fundamentals show robust profitability with a 29.31% ROE, though revenue has declined from $176.4B in 2022 to $122.7B in 2025. Analyst consensus is bullish with a $345.55 price target, and the company maintains a solid balance sheet with $4.66B in cash.
VLO's outlook is supported by tight fuel supplies and healthy demand, with projected 2026 net income of $7.2B. Key risks include volatile energy prices and potential regulatory pressures. The stock offers growth potential but faces headwinds from revenue declines and geopolitical factors affecting the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
